A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)
Xiamen Ophthalmology Center Affiliated to Xiamen University
Phase
Observational
Started
2026-03-01
Last updated
2026-03-09
Condition(s) studied
Dry Eye Disease
Study summary
Perfluorohexyloctane eye drops is the only drug in China approved for treating Dry Eye Disease (DED) related to Meibomian Gland Dysfunction (MGD), its efficacy and safety in the clinical practice of treating DED related to MGD in the real world, whether in combination with or without various other treatment methods (other drugs or physical therapy) , remain to be explored.
This study aims to collect data on the treatment of DED related to MGD with perfluorohexyloctane under real medical conditions. Through analysis, it seeks to obtain clinical evidence of the product's application value and potential benefits or risks, providing evidence for the treatment of DED elated to MGD with perfluorohexyloctane under real medical conditions.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patients who meet the diagnostic criteria for meibomian gland dysfunction (MGD) as stipulated in the "Expert Consensus on Diagnosis and Treatment of Meibomian Gland Dysfunction in China (2023)"
2. Patients who meet the diagnostic criteria for dry eye as stipulated in the "Clinical Expert Consensus on Dry Eye in China (2020)"
3. Be at least 18 years old.
4. Voluntarily participate in this study and sign a written informed consent form.
Exclusion Criteria:
1. Patients who have a history of allergy to any component of the drugs or tests intended for use in the study (such as perfluorohexyloctane, fluorescein);
2. Patients who used perfluorohexyloctane eye drops within 2 weeks before enrollment;
3. Patients who have participated in or are currently participating in clinical trials of other drugs or devices within one month;
4. Situations where researchers determine that may pose significant risks to patients, confuse the trial results, or seriously interfere with patients' participation in the trial (including language barriers).
Primary outcome measure(s)
Incidence of Treatment-Emergent Adverse Events (TEAEs) — Week 12
Incidence of adverse events assessed by the investigator as related to the study drug — Week 12
Uncorrected Visual Acuity [UCVA] — Week 12 Visual acuity will be assessed without any refractive correction using the Standard Logarithmic Visual Acuity Chart and scored as the LogMAR value. The measurement will be taken for each eye separately.
Intraocular Pressure [IOP] — Week 12 Intraocular pressure will be measured using Goldmann Applanation Tonometer (GAT) and recorded in millimeters of mercury (mmHg). Each measurement will be performed three times\] per eye and the average value will be used for analysis.
Fundus Examination Findings — Week 12 Fundus examination will be performed under small pupil conditions using direct ophthalmoscopy or indirect ophthalmoscopy. The examination will assess the optic disc, macula, retinal vessels, and peripheral retina . Findings will be documented descriptively.
Change in SPEED (Standard Patient Evaluation of Eye Dryness) Questionnaire Score at week 12 — Baseline and Week 12 Mean change from baseline in the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire total score. The SPEED assesses the frequency and severity of dry eye symptoms (dryness, grittiness, soreness, burning). The total score ranges from 0 to 28, with higher scores indicating more severe symptoms.
Trial sites (1)
Facility
City
Region
Status
Xiamen Eye Center Affiliated to Xiamen University
Xiamen
China
More Xiamen Ophthalmology Center Affiliated to Xiamen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.